Secreted and transmembrane protein 1 (SECTM1)

Secreted and transmembrane protein 1 (SECTM1) is a type I transmembrane glycoprotein found as both membrane-bound and secreted isoforms, primarily localized in the Golgi apparatus but also found in soluble form in extracellular environments[1][2]. Its N-terminus contains two immunoglobulin-like domains, and its expression is strongly inducible by interferon gamma (IFN-γ) through a STAT1-dependent mechanism, particularly in immune cells and certain cancer cell lines[1]. SECTM1 serves as a potent costimulatory ligand for the CD7 receptor on T cells and natural killer (NK) cells, directly enhancing cell proliferation and cytokine production essential for immune responses[1][3]. It can also synergize with CD28, leading to augmented T cell functions, including increased interleukin-2 production. SECTM1 has been implicated as a biomarker for poor prognosis in cancers such as esophageal squamous cell carcinoma, associating with immune cell infiltration and modulation of macrophage polarization[3]. Although not currently targeted by approved drugs, it is considered a promising target for therapeutic intervention in immune-related and cancer disorders. Caution is advised due to its dual role in immune activation and tumor progression[1][3].

Other names

K12Protein K-12K12 proteintype 1a transmembrane proteinSECTMSecreted and transmembrane 1SECTM1

Costimulatory ligand for CD7 (promotes T and NK cell activation), Synergizes with anti-CD28 (increases T cell proliferation and cytokine secretion), Immune modulation via IFN-γ/STAT1 pathway